ALS News Today

First ALS patient dosed in study of experimental gene therapy VTx-002

The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy for amyotrophic lateral sclerosis.

Coya Therapeutics Details ALS Combo Immunotherapy Plan, Highlights Early Biomarker Signals in Webinar

Speakers on a Coya Therapeutics (NASDAQ:COYA) webinar outlined the company’s scientific rationale and clinical development ...
GEN

Organ-Chip ALS Model Uses Patient iPSCs to Uncover Early Disease Progression

Amyotrophic lateral sclerosis (ALS) remains one of the most devastating and biologically elusive neurodegenerative diseases. Despite decades of research, its underlying mechanisms are still not fully ...

I AM ALS's Push for Progress Campaign Reaches Major Milestone, Securing Unprecedented Federal Research Investment and Bringing Total Secured Since Founding To $1.6 Billion

I AM ALS announced a major milestone in its Push for Progress campaign: thanks to our community of advocates and partners, we've secured $313 million in funding for ALS research in the 2026 federal ...
Hosted on MSN

New drug may slow progression of ALS in small group of patients, study finds

A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...

UK-Based Vesalic Limited Emerges from Stealth with Landmark Discovery of Potential Non-CNS Driver of Motor Neuron Diseases, including ALS, and Breakthrough Therapeutic and ...

This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo in ALS ...
Yahoo

New Study Links Immune System To ALS Progression, Offering Hope For Treatments

Add Yahoo as a preferred source to see more of our stories on Google. Wheelchair, isolated view Image by Kub The Shadow Simple ManShutterstock A newly published study says that the body’s own immune ...
Business Wire

Mounting Evidence Demonstrates Neuvivo’s NP001 Spares Lung Function and Substantially Extends Survival in ALS Patients

Subset analysis of patients whose ALS did not progress from a long-term survival study showed NP001 saved lung function and extended life by 22 months vs. a control group (~70% on riluzole) NP001 ...
Science Daily

Experimental drug may benefit some patients with rare form of ALS

Some patients with a rare form of ALS benefited from an experimental therapy, with biomarker evidence of reduced injury to neurons and even limited functional recovery. When Columbia neurologist and ...
ALS News Today

Inflammatory bacterial sugar in gut may drive ALS risk: Study

An inflammatory sugar molecule produced by certain gut bacteria may play a key role in driving ALS, a study found.

Grey's Anatomy actor Eric Dane opens up about his ALS progression: What you need to know about the disease

Eric Dane has revealed that he has lost the function of his right arm because of ALS. Here is what you should know about the ...
STAT

Autoimmune responses found in ALS, pointing to a new way to view the deadly disease

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Researchers have found that patients with amyotrophic lateral sclerosis have ...